FMT for MS Patients (MS-FMT)
Fecal Microbial Transplantation for Relapsing Multiple Sclerosis Patients - a Placebo-controlled, Double-blinded, Randomized Trial
연구 개요
상태
정황
상세 설명
Fecal Microbiome Transplants: Patients will undergo pretreatment with Amoxicillin/Clavulinate (or matched placebo) for 5 days followed by a bowel cleanse with PEGLYTE. Patients will undergo allogeneic or autologous fecal transplants. Patients will be dosed with FMT oral capsules approximately 48 hours after antibiotic treatment has stopped. Following the FMT capsule treatment on day 1, patients will be administered a repeat oral capsule or placebo dose at 3 weeks. Oral omeprazole or omeprazole placebo will be given 1 hour prior to the baseline and 3 week dose. This will be done to ensure full engraftment of the transplant.
Participants will be seen at baseline, 3 weeks, 6 weeks, 3 months, 6 months and 12 months. A series of neurological tests will be performed for safety measures. In addition to this, MRIs will be completed at baseline, 6 weeks and 12 months. Blood, urine and stool samples will also be collected for data analysis and safety measures.
연구 유형
등록 (예상)
단계
- 2 단계
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- 18 - 55 years of age
- Have an expanded disability status scale (EDSS) of < 6
- Have a diagnosis of relapsing multiple sclerosis
- Have evidence of radiographic activity within the 12 months on MRI (new/enlarging T2 lesion or gadolinium enhancing lesion)
- Eligible to start/starting an injectable DMT
- Not on a DMT currently and/or not on a DMT in last 6 months
- Ability to swallow capsules
Exclusion Criteria:
- Unable to provide informed consent
- Does not pass the standard MRI screening questionnaire
- Other disease that can affect GI permeability (such as Inflammatory Bowel Disease, Crohn's disease, ulcerative colitis, indeterminate colitis or microscopic colitis, celiac disease)
- Expected requirement for antibiotics within 3 months (chronic suppressive therapies, elective prosthetic joint insertion)
- Toxic megacolon, small bowel ileus
- Penicillin allergy
- Omeprazole allergy
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 기초 과학
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
위약 비교기: Autologous Transplants
|
Healthy donor stool will be processed and placed into capsules.
Participants stool will be processed and placed into capsules.
|
|
활성 비교기: Allogeneic Transplants
|
Healthy donor stool will be processed and placed into capsules.
Participants stool will be processed and placed into capsules.
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Changes in T2 Lesions - MRI
기간: Baseline, 6 weeks, 12 months
|
Assess the number of new/enlarging/gad enhancing T2 lesions.
We will be comparing baseline to 6 weeks and 6 weeks to 12 months.
|
Baseline, 6 weeks, 12 months
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Blood Brain Barrier - MRI
기간: Baseline, 6 weeks, 12 months
|
We will assess the integrity of the blood brain barrier through MRI from baseline to 6 weeks and 6 weeks to 12 months.
|
Baseline, 6 weeks, 12 months
|
|
Neurofilament Light Serum Levels
기간: Baseline, 6 weeks, 3 months, 12 months
|
As a biomarker of neuronal damage neurofilament light chain levels will be detected. Peripheral blood will be collected in appropriate tubes at baseline, 6 weeks, 3 months and 12 months and processed for serum. Once collected all samples will be sent to the University of Ottawa where a Simoa NfL assay will be undertaken on their Simoa Analyzer. Patients with multiple sclerosis have been shown to have increased intestinal permeability, likely due to a reduction in butyrate-producing bacteria. A decrease in butyrate producing bacteria has been shown to be associated with increased intestinal permeability. Relapsing-remitting MS patients have been shown to have increased intestinal permeability, which may allow dietary and microbial antigens from the intestinal lumen to pass into the blood stream and cause autoimmune responses in MS patients. This may prime the immune system to develop a humoral response to certain bacteria. |
Baseline, 6 weeks, 3 months, 12 months
|
|
Intestinal Permeability
기간: Baseline, 6 weeks, 12 months
|
Small Intestine Permeability: Mannitol/Lactulose administration will be used and urine will be collected to measure small intestine permeability.
For small intestine permeability patients will be instructed to drink lactulose solution and collect the urine throughout the night and first thing in the morning.
A proper collecting bottle will be provided.
Once the urine sample bottle reaches the laboratory University Hospital the total volume will be measured and an aliquot of 30mL total, 10mL in each sterile urine container (no other additives) will be separated and stored at -20C and sent on dry ice to Dr. Meddings laboratory at Calgary, Alberta.
All biological material will be transported according to biosafety regulations.
|
Baseline, 6 weeks, 12 months
|
|
IgA Microbiota
기간: Baseline, 3 weeks, 6 weeks, and 12 months
|
IgA Microbiota analysis: IgA bound bacteria will be detected and sorted (magnetic beads or flow cytometry) using anti-IgA (pan-IgA, detect monomer and secreted multimer (Miltenyi clone: IS11-8E10).
Sorted IgA bound bacteria will be stored, and the DNA extracted in one batch at the end of the study.
Changes in the composition of IgA bound bacteria for each patient will be determined using the previously mentioned methods.
(Rojas, et al. 2018; Planer, et al. 2016)
|
Baseline, 3 weeks, 6 weeks, and 12 months
|
|
Stool Microbiome
기간: Baseline, 3 weeks, 6 weeks, 3 months, 6 months, 12 months
|
Gut microbiota analysis before and after FMT: Toilet paper samples will be collected from patients' at baseline and 1-2 days before each scheduled appointment (Al et al. 2018).
Patients will store the toilet paper inside of DNA free plastic bags and keep them at 4 °C in the refrigerator until the time of their appointment (alternatively, the samples can be mailed in to the lab, but one method must be chosen for all of the samples collected).
Toilet paper samples will be collected from the FMT donor every time they drop off a stool sample for donation.
DNA from the toilet paper samples will be extracted in one batch at the end of the study and sent for Illumina Mi-Seq next-generation sequencing of the V4 region of the 16S rRNA gene.
Changes in the composition of gut bacteria will be determined using custom R scripts.
|
Baseline, 3 weeks, 6 weeks, 3 months, 6 months, 12 months
|
|
Metabolomics
기간: Baseline, 3 weeks, 6 weeks, 3 months, 6 months, 12 months
|
Metabolomics: Serum will be collected for metabolomic analysis.
Metabolomics can be used to identify biomarkers of MS and may provide us with information about which patients are more likely to respond to FMT therapy.
Butyrate producing bacteria have been shown to be in lower relative abundance in MS patients and concentrations of short-chain fatty acids in stool and will be investigated before and after FMT.
|
Baseline, 3 weeks, 6 weeks, 3 months, 6 months, 12 months
|
|
Metabolomics
기간: Baseline, 3 weeks, 6 weeks, 3 months, 6 months, 12 months
|
Metabolomics: Urine will be collected for metabolomic analysis.
Metabolomics can be used to identify biomarkers of MS and may provide us with information about which patients are more likely to respond to FMT therapy.
Butyrate producing bacteria have been shown to be in lower relative abundance in MS patients and concentrations of short-chain fatty acids in stool and will be investigated before and after FMT.
|
Baseline, 3 weeks, 6 weeks, 3 months, 6 months, 12 months
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (예상)
기본 완료 (예상)
연구 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- MS-FMT 002
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
다발성 경화증에 대한 임상 시험
-
Sanko University완전한MULTİPLE SCLEROSİS | BALANCE | 유효성 | 신뢰도터키 (Türkiye)
-
University Hospital, Montpellier종료됨제1형 당뇨병 | Basal-bolus multiple-dily 인슐린 주사 | 인슐린 펌프(CSII)프랑스
Fecal Microbial Transplants에 대한 임상 시험
-
UMC UtrechtZimmer Biomet초대로 등록